Compare PTCT & BCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | BCO |
|---|---|---|
| Founded | 1998 | 1859 |
| Country | United States | United States |
| Employees | N/A | 125 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.8B |
| IPO Year | 2006 | 2010 |
| Metric | PTCT | BCO |
|---|---|---|
| Price | $72.06 | $114.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 2 |
| Target Price | $80.65 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 1.2M | 590.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.95% |
| EPS Growth | ★ 264.48 | 29.20 |
| EPS | 0.90 | ★ 1.84 |
| Revenue | $264,734,000.00 | ★ $3,562,300,000.00 |
| Revenue This Year | N/A | $7.22 |
| Revenue Next Year | $17.70 | $5.92 |
| P/E Ratio | $80.71 | ★ $61.93 |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $47.94 | $91.05 |
| 52 Week High | $90.87 | $136.37 |
| Indicator | PTCT | BCO |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 53.00 |
| Support Level | $68.16 | $106.86 |
| Resistance Level | $72.09 | $116.87 |
| Average True Range (ATR) | 2.96 | 4.98 |
| MACD | 0.08 | -1.07 |
| Stochastic Oscillator | 50.82 | 40.07 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provide BGS services and BGS activity in Latin American countries. It derives maximum revenue from the North America segment.